NO960545L - Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin - Google Patents

Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin

Info

Publication number
NO960545L
NO960545L NO960545A NO960545A NO960545L NO 960545 L NO960545 L NO 960545L NO 960545 A NO960545 A NO 960545A NO 960545 A NO960545 A NO 960545A NO 960545 L NO960545 L NO 960545L
Authority
NO
Norway
Prior art keywords
administration
effects associated
treatment
adverse effects
extracellular hemoglobin
Prior art date
Application number
NO960545A
Other languages
English (en)
Other versions
NO960545D0 (no
Inventor
Michael J Gerber
Original Assignee
Somatogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somatogen Inc filed Critical Somatogen Inc
Publication of NO960545D0 publication Critical patent/NO960545D0/no
Publication of NO960545L publication Critical patent/NO960545L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelse angår fremgangsmåter til å rette alvorlighet og frekvens av skadelige virkninger assosiert med administrering av ekstracellulært hemoglobin som omfatter å administrere et glatt muskelavslappende middel. Foretrukkede glatte muskelavslappende midler er terbutalin og nifedipin, som kan administreres i en profilaktisk behandling, vedvarende behandlingskur eller en intermitterende behandlingskur.
NO960545A 1993-08-13 1996-02-12 Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin NO960545L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10613893A 1993-08-13 1993-08-13
PCT/IB1994/000239 WO1995005167A2 (en) 1993-08-13 1994-08-09 Treatment of adverse effects associated with administration of extracellular hemoglobin

Publications (2)

Publication Number Publication Date
NO960545D0 NO960545D0 (no) 1996-02-12
NO960545L true NO960545L (no) 1996-02-29

Family

ID=22309699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960545A NO960545L (no) 1993-08-13 1996-02-12 Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin

Country Status (8)

Country Link
US (1) US5750132A (no)
EP (2) EP0784983A3 (no)
JP (1) JPH09501441A (no)
AU (2) AU7194694A (no)
CA (1) CA2167716A1 (no)
IS (1) IS4198A (no)
NO (1) NO960545L (no)
WO (1) WO1995005167A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026195A1 (en) * 1994-03-28 1995-10-05 Baxter International Inc. Therapeutic use of hemoglobin in the treatment of blood vessel blockage
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
FR2809624B1 (fr) * 2000-05-31 2002-08-02 Centre Nat Rech Scient Utilisation comme substitut sanguin d'une hemoglobine extracellulaire de poids moleculaire eleve
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7494974B2 (en) * 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
EP2427483B1 (en) * 2009-05-07 2015-03-11 Hemarina Novel heamoglobin and uses thereof
WO2013036383A1 (en) * 2011-09-06 2013-03-14 Bing Lou Wong Oral delivery for hemoglobin based oxygen carriers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4965065A (en) * 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US5043358A (en) * 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0561245A1 (en) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Blood substitutes comprising recombinant hemoglobin
NL8901174A (nl) * 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2080589A1 (en) * 1990-04-16 1991-10-17 Joseph De Angelo Expression of recombinant hemoglobin in yeast
DE69132763D1 (de) * 1990-12-20 2001-11-15 Univ Alabama Res Foundation Bi Transgenes, vernetztes hämoglobin
AU2140492A (en) * 1991-05-14 1992-12-30 Biopure Corporation Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10

Also Published As

Publication number Publication date
EP0717619A1 (en) 1996-06-26
EP0784983A3 (en) 2001-03-21
WO1995005167A2 (en) 1995-02-23
NO960545D0 (no) 1996-02-12
WO1995005167A3 (en) 1995-04-13
AU7194694A (en) 1995-03-14
IS4198A (is) 1995-02-14
AU7011098A (en) 1998-07-30
US5750132A (en) 1998-05-12
EP0784983A2 (en) 1997-07-23
CA2167716A1 (en) 1995-02-23
JPH09501441A (ja) 1997-02-10

Similar Documents

Publication Publication Date Title
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
NO960899D0 (no) Fremgangsmåte for regulering av gastrointestinal motilitet
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
WO1999013875A8 (en) Use of nitroxides for the treatment of essential hypertension
AU2003239393A1 (en) Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
SG152270A1 (en) Immunemodulating oligosaccharides
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
ATE141792T1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen
GR3034508T3 (en) Use of insulin sensitizing agents to treat hypertension.
SI1572167T1 (sl) Transdermalni buprenorfinski dozirni reĹľim za analgezijo
NO960545L (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
MY125984A (en) Pharmaceutical solutions of levosimendan.
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
NO931886L (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
NO20044481L (no) Azabisykliske, azatrisykliske og azaspirosykliske derivater av aminosykloheksan-NMDA, -5HT3 og neuronale nikotinreseptorantagonister.
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
NO981687L (no) Lubeluzol N-oksid
SE9101341D0 (sv) New medicinal use
JO1917B1 (en) A different method for controlling high levels of bilirubin in the blood in newborns
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ATE234619T1 (de) Verwendung von spiramyeine in von h.pylori verursachten magen und darm beschwerden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application